TG Therapeutics, Inc.

Greetings, and welcome to the TG Therapeutics third quarter conference call and webcast. At this time, all participants are enlisted in only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Jenna Bosco. Please go ahead.

Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the third quarter 2024 financial results are Michael Weiss, our Chairman and Chief Executive Officer, Adam Waldman, our Chief Commercialization Officer, and Sean Power, our Chief Financial Officer. Following our Safe Harbor statement, Mike will provide an overview of our recent corporate developments, Adam will share an update on our commercialization efforts, and Sean will give a summary of our financial results before turning the call over to the operator to begin the Q&A. Before we begin, I'd like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, including sales performance, projected milestones, revenue guidance, development plans, and expectations for our marketed product. TG cautions that these forward-looking statements are subject to risks that may cause our actual results to differ materially from those indicated. Factors that may affect TG Therapeutics operations include various risk factors that can be found in our SEC filings. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any later date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on TG's website, www.tgtherapeutics.com, where it will be available for the next 30 days. With that, I'd like to turn the call over to Mike Weiss, our CEO.

Thank you, Jenna, and good morning, everyone, and thank you for joining us for our quarterly earnings call. We're excited to share with you the results of another quarter of growth and execution of our BrionV launch. The positive feedback and uptake for BrionV in the marketplace continues to outpace our expectations, and the strong data presented during the annual experts meeting from the ultimate one and two trials and the enhanced phase 3B trial both evaluating Briomvi in individuals with relaxing forms of MS, continues to strengthen our belief in the long-term value of Briomvi. We remain highly focused on the commercial success of Briomvi, and I'm excited to share with you our current progress, as well as our future plans to continue to grow Briomvi and shareholder value. Let's kick things off with a brief review of the quarterly sales. I'm happy to report that Briomvi third quarter, U.S., Net sales were 83.3 million. Adam Waldman, our chief commercialization officer, will join shortly to write a full commercial update and year-end guidance. But I wanted to say that I'm extremely pleased with the continued commercial launch effort. The team continues to execute on our phased launch plan, setting us on what we believe is a path for continued growth and strong momentum heading into the end of the year and into 2025. And further toward our long-term goal of becoming the number one prescribed anti-CD20 in terms of dynamic market share. To that end, let's discuss some of the brianna data presented at the recent ECTRIMS annual meeting. As I alluded to earlier, we presented two important data sets during the meeting. The first was a long-term follow-up data from our open label extension study from the ultimate one and two phase three trials, which, as a reminder, were the core trials that supported the approval of Realme for individuals with relapsing forms of MS. After five years of Realme treatment, 92% of patients were free from disability progression. And in the fifth year of treatment, an annualized relapse rate of 0.02 was observed, which is equivalent to one relapse occurring every 50 years of treatment. And importantly, the overall safety profile remained consistent over five years of continuous pre-OMB treatment, with no new safety signals emerging with prolonged usage. As we've stated previously, we believe we have set the standard for convenience in IV CD20 therapy, and we continue to look for ways to further streamline the patient experience. At ECTRIMS, we updated data previously presented to AN in April from our enhanced study, showing that individuals with relapsing forms of MS who were B-cell depleted on their current anti-CD20 therapy and were switched to BrionV were able to tolerate the one-hour BrionV infusion without first receiving the four-hour introductory dose. Currently, all IV CD20s used to treat MS require two infusions in the first two weeks to initiate therapy. This approach would only require one visit to start BrionV. Additionally, at ECTRIMS, we presented data for the first time on a faster 30-minute BrionV infusion from our enhanced trial. The data presented, while still preliminary, showed that the first maintenance dose of BrionV given as a 30-minute infusion, as opposed to one hour, was well-tolerated, with all infusion-related reactions being mild, grade 1, and resolved completely. We have now treated over 50 individuals with RMS with 30-minute BrionV and look forward to presenting updated data at a future medical conference. As you can imagine, more testing, including randomized trials, will be needed to incorporate these potential updates into our label, but hopefully this highlights our longer-term vision to continually seek to improve the patient journey with BrionV. and maintain what we believe is a best-in-class profile. And further to achieving that goal, I'd like to remind everyone that we are also developing a sub-Q version of BreonV. While the majority of individuals with MS choose IV CD20 delivered every six months, which is how BreonV is currently offered, and we expect that to continue, the at-home self-administered sub-Q market is meaningful. Accordingly, we believe that offering an at-home self-administered sub-Q BRIOMV would open up a new market opportunity for us. We expect to be able to provide an update from our BRIOMV sub-Q bioequivalent study by early next year. And if all goes well, we'd be targeting a pivotal trial commencing in the middle of 2025. And finally, beyond BRIOMV on the R&D front, we previously shared that the US FDA has cleared our investigational new drug application IND for Azercel, and off-the-shelf allogeneic CD19 CART T-cell therapy for the treatment of autoimmune diseases. The team has been working hard to move this forward, and we are targeting launching a phase one study around the end of this year or early next year, starting in individuals with progressive MS. This is an exciting new opportunity that we believe may offer a new treatment for individuals with progressive MS who have few options. Switching gears a little bit, I want to highlight a recent transaction related to manufacturing and supply. As you may be aware from our public filings, we currently manufacture Brionvi at Samsung Biologics in South Korea, who are recognized as the global leaders in biologics manufacturing and who have been and continue to be a great partner to TG. As Brionvi continues to grow, as we continue to believe the blockbuster potential of Brionvi, From a risk management standpoint, we felt it was time to engage a secondary manufacturer of BrionV. Accordingly, we are happy to announce we have secured Fujifilm DioSynth Biotechnologies as a second manufacturer of BrionV at the facility base here in the United States. As we continue to expand our commercialization efforts in MS and think about the future of BrionV, we believe this is an important next step that will continue to support our growth plans and provide additional security for our drug supply. In closing, I want to thank all of our TGers for their hard work and commitment to people living with MS. Our progress is a testament to our collective efforts, and I'm excited about the path forward. Through your efforts, TG is poised to become a new leader in the MS market, focused on developing and delivering innovative therapies for multiple sclerosis. With that, I'll hand the call over to Adam Waldman, our Chief Commercialization Officer, to walk you through a commercial performance in more detail. Thank you. Adam, go ahead.

Yep. Thank you, Mike. I'm excited to share the continued commercial success we've experienced with Breonvi and the steps we're taking to drive future long-term growth. Since its launch, Breonvi has consistently exceeded our expectations, with Q3 marking another strong quarter of sequential revenue growth. As Mike mentioned, we achieved second quarter net sales of $83.3 million, reflecting approximately 15% quarter-over-quarter growth and over 230% growth from the same quarter last year, solidifying Breon B as the fastest-growing DMT in the U.S. MS market. And while we did observe some expected summer dynamics in the third quarter, where new patient visits tend to slow, particularly during July and August, enrollments into our hub rebounded in September, and that momentum continued into October, where we saw record enrollment months. We continue to see steady growth in new prescribers and treatment centers, now reaching nearly 1,100 prescribers across approximately 600 centers, including 95% of the top 100 MS centers since launch. Encouragingly, two-thirds of the new prescribers in Q3 came from the hospital setting, which is now our fastest-growing segment and accounts for approximately 55% of our overall business. We continue to believe in BrionV's best-in-class profile, including its high level of efficacy, well-established safety profile, and a one-hour infusion every six months, attributes which we believe strongly resonate with healthcare providers looking for a convenient yet highly effective treatment option. We are particularly excited to see the overwhelming positive response to BrionV at the Actrims Conference in September. As Mike mentioned, BRIAMBI was featured prominently, and the clinical data we presented garnered strong interest from healthcare providers and thought leaders in the MS community. Several key takeaways emerged from the conference from a commercial perspective. First, we believe the enhanced trial, which showed the potential for BRIAMBI to have a rapid 30-minute infusion, could represent a significant enhancement to our profile. Second, the enhanced trial showed the potential to switch from a CD20 to BRIAMBI without requiring a loading dose. We believe this will make switching potentially easier for many patients who may not be satisfied with their current CD20 therapy. And finally, the open-label extension presentation underscored BRIAMBI's long-term efficacy and safety, reinforcing its potential best-in-class profile. The data demonstrated an impressive annualized relapse rate of just 0.02 at five years, equivalent to one relapse for 50 patient years, along with consistent five-year safety data. We believe this information reinforces BRIAMBI's value proposition and will particularly resonate with physicians and patients who seek established long-term data before adopting new therapies. The visibility and recognition BRIAMBI received at Ekstrom has certainly strengthened our confidence in its long-term positioning as the preferred anti-CD20 therapy in relapsing forms of MS. Another contributing factor to BRIAMBI's growing success is the expansion of our commercial infrastructure. Excuse me. Over the last two years, we have nearly doubled our commercial field team, ensuring that we can adequately support the rising demand for BrionV and increase our reach within key MS treatment centers. This expansion has allowed us to increase our presence across the US market. As a result, we've been able to engage and educate more physicians on the BrionV product profile. Alongside the commercial team expansion, we have also started to increase our investments in patient awareness, recognizing that informed patients are often key drivers in treatment decisions we have launched targeted awareness campaigns aimed at educating patients on the benefits of BRIAMVI. These campaigns are aimed at empowering patients to have informed discussions with their healthcare providers. We believe that by raising awareness directly among patients, we can further accelerate adoption and ensure that more individuals living with relapsing forms of MS can benefit from BRIAMVI's unique profile. Our patient-centric strategy will remain a focal point as we continue expanding our outreach efforts in 2024, and we plan to significantly increase investment in these activities in 2025 and beyond. Since launch, we've made significant strides in ensuring BRIOMB's availability and access. As I mentioned previously, this has always been a prioritized area for us, and we are pleased that we maintain 95% coverage with national and regional payers. Additionally, our team is doing an exceptional job facilitating the reimbursement process and working with customers and patients to make sure patients can access Briambi. We have worked diligently to streamline the patient journey, ensuring that Briambi is accessible with minimal delay, which has helped sustain our patient adherence and satisfaction. Our time to infusion continues to decrease, and our persistence at week 24 continues to exceed our expectations. Our performance this quarter reinforces our belief that Briambi's profile continues to resonate in the market, and our commercial organization is very capable of continuing to deliver results. As we look to Q4 and beyond, we expect to see continued growth, and accordingly, we are raising our full-year guidance for Beyond the Net US Sales to 300 to 305 million. We continue to exceed our expectations and have raised this number substantially from our original full-year guidance of 220 to 260 million provided in early 2024. We continue to be excited about what lies ahead. Our foundation is strong. We're poised to capture more growth in the coming quarters, and we believe we are well-positioned to grow Briambi into a blockbuster brand. In conclusion, I want to thank our team for their dedication and hard work. Their outstanding efforts are contributing to the positive experience with Briambi and confidence in our organization. I also want to thank the healthcare providers and their patients for their trust in TG Therapeutics. Together, we will continue to improve outcomes for those in need. We certainly have more work to do, but we're focused and extremely motivated to continue to work every day to bring re-envy to those living with MS and their families. With that, I'll turn the call over to Sean Power, our CFO.

Thank you, Adam, and thanks again to everyone for joining us. Earlier this morning, we reported our detailed third quarter 2024 financial results, which can be viewed on the Investors and Media section of our website. This morning, I'll start by highlighting our Q3 revenue. As Adam detailed earlier, we are pleased to report third quarter BREE-MV net product revenue of $83.3 million for the three-month period, bringing our year-to-date nine-month BREE-MV net product revenue to $206.4 million. Turning now to our income statement for the period, we are pleased to report that we generated net income in both the three and nine-month periods ending September 2024. For the three months ended September 30, 2024, our GAAP net income was approximately $3.9 million, or two cents per diluted share. When excluding non-cash items, net income for the three-month period was approximately $15.7 million. Our OPEX during the quarter, excluding non-cash items, came in at the low end of our guided range at approximately $50 million. Our OPEX for the first nine months of 2024 is approximately $155 million. And for the full year, we expect our OPEX to come in well below the guidance of approximately $250 million. And finally, I'll close by touching briefly on our cash position. We ended the third quarter with approximately $341 million in cash, cash equivalents, and investment securities. which we believe provides us with a strong financial position to support the BRIAMBI commercialization, our research and development efforts, and our continued business operations for the foreseeable future. On a related note, I'd like to briefly touch on our share repurchase program, which recommenced during the third quarter. We began slowly buying shares back during the third quarter and will continue with a measured approach for the foreseeable future. Although the share amounts repurchased during the third quarter were minimal, we do expect this program to continue throughout the remainder of the year and into 2025. With that, I will now turn the call back over to the conference operator to begin the Q&A.

Thank you. Now we'll be conducting a question and answer session. If you'd like to be placed in the question queue, please press star 1 on your telephone keypad. We ask you please ask one question, one follow-up, then return to the queue. Once again, that's star one to be placed into question queue, and please ask one question and one follow-up, then return to the queue. For participants using speaker equipment, it may be necessary to take yourself off speakerphone before pressing star one. Our first question today is coming from Ed White from H.C. Wainwright. Your line is now live.

Good morning. Thanks for taking my question. First, I wanted to ask a big picture question. You mentioned in the press release that you expect to see continued growth in 2025. I just wanted to get your thoughts on the size of the anti-CD20 market in MS in 2025 and your thoughts on market share, not only for Briumde, but also IV versus sub-Q.

Thanks, Ed, for the question. Adam, you want to take a crack at that one?

Sure. Good morning, Ed. Sure. So, big picture, I mean, we see CD20s continuing to grow. You know, it's in the low 50% of dynamic share today. We see no reason that that can't continue to grow to, you know, mid-50s to even 60%. You know, I think the momentum continues behind the class Um, you know, as far as our market share, uh, growth, I mean, we're, we're about, you know, 15% of the, uh, you know, CD 20 market today. And then, and you know, we think we have a lot of room to grow.

Okay. Thanks. And, uh, just a question on the, uh, announced, um, Fujifilm, um, secondary us based manufacturing. Your gross margins have been pretty consistent this year, quarter over quarter. Will this agreement have any impact on gross margin going forward?

Sean, want to tackle that?

Thanks for the question. In the near term, absolutely not. We'll have some upfront expenditures associated with that, but that will, of course, run through R&D, and in the long term, we think gross margins would remain consistent. So, short answer to your question is no, no real impact on gross margin.

Yeah, and I forgot to answer one part of your question, which was the IV to sub-Q. You know, we believe it's around 70% IV to sub-Q in terms, and we do still believe it is as Mike said in his remarks, the clear patient preference today, and we see that continue.

Great. Thanks, Adam, and thanks to everyone. Congratulations on the quarter. Thanks, Ed.

Thank you. Next question is coming from Michael DeFiore from Evercore ISI. Your line is now live.

Hey, guys. Thanks so much for taking my question, and congrats on the quarter. Two for me. Were there any inventory channel dynamics during free queue? And separately, what was a TRX script count in free queue, and how many new patient scripts have been received in the hub? I noticed that wasn't included in your print this morning. Thank you.

Sure. Thanks for the question. Adam, want to tackle those, the inventory and TRX?

Yeah, first question, Michael. There are no changes in inventory in the quarter. All distributors are at normal inventory levels. And as far as the enrollments, we're going to move away from providing that number. I think as we continue to grow our hospital business, our capture rate continues to go down because hospitals are just less likely to use our hub. So we just don't think that this is going to be an accurate measure going forward. I think directionally it can help, certainly, but I think in sort of using it as a way to sort of garner whether we're growing or not growing, it's just with the capture rate fluctuating and more and more hospitals coming into play that are certainly just not using it. We've decided to focus more on the revenue guidance as we've done over the past several quarters and will continue to do going forward. But we just don't think hub enrollments are – it was good in the beginning. I think certainly in the beginning where we had a much higher percentage of our business coming from private practices that used the hub much more consistently, it was a good measure. As we continue to go out here, As more, you know, I said in our remarks, about 55% of our business now is coming from hospitals. It's the fastest growing of our segment. And they're just less likely to use our hub. And that creates some difficulty in interpreting the information out of the hub enrollment data.

Got it. Very helpful. Thank you.

Thank you. Next question is coming from Eric Joseph from J.P. Morgan. Your line is now live.

Hi, good morning. Just picking up on the plan to adapt for a faster infusion time, just coming out of the enhanced update of eCTRIMS. Can I get you to elaborate a little bit more on sort of what might be needed to support a label indication for either a shorter infusion or skipping a loading dose for switch patients. You mentioned possibly needing randomized data. Would the focus there be exclusively on safety, and would you need to assess more than one infusion per patient as part of a trial like that?

Yeah, thanks for the question, Eric. So the answer to the last part of your question, will we need more than one infusion, is probably unclear today, but I don't think so. I don't think we'll need more than one infusion per patient to tell on the safety. And yes, it's primarily a safety study. For faster infusions, historically, when you've They've been done before with other companies, and they do require randomized trials, and they usually are looking at safety and tolerability. I think that's what our expectations are.

Okay, great. And maybe a follow-up, if I could, with respect to the sub-Q initiative. Can you talk a little bit about sort of what you are tracking in addition to safety to kind of verify – or sort of assess how long of a dosing interval you could ultimately move forward with in a pivotal study?

Yeah. So again, with SubQ, we're looking at primarily the bioequivalent. So again, it's just the amount of material required to match the PK. And yes, that will determine the tolerability. If the material is put too much in, you would at some point start to see a deterioration in tolerability at the injection site. But the primary focus is the bioavailability. That will tell you how much material you need to load into the injection. That will ultimately, as you mentioned, impact how tolerable it is. all of those pieces will come together at some point soon. We're hoping, like I said, to be able to share that data early next year. But those are basically the three pieces that have to come together.

Is there a PD component? Are you looking at a sort of B cell decline?

Yeah, I could share with you that B cell decline is not an issue at any real dose level.

Okay. Thanks for taking the questions. Thank you.

Okay. The next question is coming from Tara Bancroft from TD Calendarline. Is that live?

Hi. Good morning. Thanks for taking the questions. So thinking about your guidance, it assumes just over or I guess just under 20% sequential growth, and that's incrementally higher than, you know, the 15%. from Q3, but I was wondering, looking ahead now, should we assume steady growth like this from here on out or a similar cadence of growth like in 2025 like you saw this year and last year with a heavy Q2 and seasonal impacts? Just a bit on how you would vision near-term dynamics here would be really helpful. Thanks.

Sure. Thanks. Adam, you want to talk a little bit?

Sure. Yeah, thanks for the question, Tara. I mean, you know, we try to provide the best information we have when we have it. I think the guidance is strong and shows sequential revenue growth. We're continuing to do some things here and make some investments. And as I mentioned in my remarks around, you know, patient awareness and other things that, you know, we are hoping will continue to fuel the trajectory of the growth of this product. As I mentioned, we think we're poised to make this a blockbuster brand. And that trajectory, I think there are seasonal, if you look at the MS market in general, there are some quarterly season dynamics that are in play. You know, as I mentioned in Q3, there were some in just the summer months. you know, that can affect the exact line. But I think we are poised to grow more. We're doing things in the market that are getting traction, and we're very excited about what the future is for BrandV.

Okay, great. Thanks. And just a quick follow-up on the previous question about SubQ. You know, I understand you mentioned a lot of expectations there, which was helpful. But can you tell us what –

volume and and perhaps dosing interval that you're ideally targeting with with the subq formulation sure yeah so i mean ideally it would be as less frequently as possible um i think sort of a minimum bar uh would be certainly uh every other month i think is the minimum bar that we're targeting uh and anything less frequent than that we think would be fantastic and we'll be obviously working toward that of course but no promises. But yeah, that's the minimum profile I think would be every other month is the target for that.

Great. Thanks so much. You got it.

Thank you. Our next question today is coming from Matt Kaplan from Lattenburg-Palmer. Your line is now live.

Hey, good morning, guys. And congrats on the quarterly results. I guess for Adam, can you expand on the rates of persistence you're seeing and how it compares to other therapies in the space?

Yeah. Hey, Matt. Thanks for the question. You know, we, you know, the only compliance numbers that we have or that we've seen that are published are with the other IVCD20 competitor. And we're doing, you know, so that's been sort of our benchmark and, you know, what we were expecting. And we continue, it looks like, and again, you know, we're continuing to collect data, but it looks like we're doing at least as good, if not better, on the week 24 compliance than what's out there and published.

Okay, great. And just a follow-up on the enhanced data and the questions with respect to compliance. when you could see that incorporated into clinical practice. When do you think you could complete the studies necessary to have that available and update the label?

Yeah, thanks, Matt. So the goal would be to get those studies started sometime next year. Those studies, you know, again, with enrollment into a randomized trial of reasonable size, let's say, give or take 200 to 300 subjects. It can take at least a year, so you've got a year of enrollment. Follow-up should be short, so we should be able to follow the patients and get that data put together pretty quickly and get a filing in. So I think we're, even in the best case scenario, it's probably a two- to three-year process to get it into the label.

All right. Thanks, Mike. You got it.

Thank you. Next question today is coming from Mayank Mantani from B. Riley Securities. Your line is now live.

Good morning, Tim. Congrats on a strong quarter, and thanks for taking the question. So on the revenue split, if you are able to share between maintenance and maybe new-to-be-ungry patients, and if you are able to confirm at what juncture the maintenance patients overwhelmingly takes over the new-to-BMV patients. And did you comment by any chance on the share for new-to-CD20 versus newly-diagnosed RMS patients? And we'd love to hear any color you are seeing in the marketplace within the intra-CD20 class switch. What percent patients are up for grabs? we'd love to hear any perspective on that.

Sure. Thanks, Matt. Adam, do you want to crack?

Yeah. As far as the first question, the revenue split is still mostly new versus repeat, but we do expect in the next several quarters that that will turn upside down, right? Repeat prescriptions will start to be the the lion's share of the infusions going in the next couple quarters as we continue to stack the stacking effect and we continue to get patients coming back for week 48 and so on and so forth. But today it's still news that they're majority, but in the next several quarters we do expect repeat to increase and become the dominant amount from the revenue split perspective. I think the second question was share of newly diagnosed. Is that right, Mayak?

Yes, that's accurate.

Yeah, we haven't provided shares in newly diagnosed or new to CD20. We haven't provided those shares. And then, you know, your third question was about, you know, switching. And we do see, you know, we continue to see a sizable portion of our BrailleV business coming from switches from both Elkervis and Cosimta. And that has remained pretty steady and consistent since launch.

Yeah, I'll add to that. One of our recent surveys indicated up to 20% of those patients might be up for grabs, hence the question. And then lastly, on the biologics manufacturing expansion implication, are you able to comment on any long-term supply goals that you may have in mind between the Korea and U.S. facilities? Any way to quantify that would be very helpful, Mike. Thanks again for taking the question.

Yeah, so I don't think we have a good answer at this moment on my end, but obviously we're securing what we think is what was required for a long-term supply between both of Samsung and Dyson.

Understood. Thank you.

Thank you. Next question is coming from Corinne Johnson from Goldman Sachs. Your line is now live.

Good morning, guys. Maybe a couple from us. You talked about the bulk of growth in your patients coming from the hospital setting. I guess remind us what portion of MS patients are taking care of there, and why do you think that's been such a good source of new patient growth for you? And then my second question is, as you think about 2025, could we see steady or even maybe accelerating new patient growth on an absolute basis into year three as you get kind of like well into the launch here?

Sure. I'll start with the second question. Yeah, I mean, certainly we do believe that we can have accelerating new patient starts as we get into 2025. We've always felt that just generally speaking, you know, the more patients that go on Breonvy, the more patients will go on Breonvy. So there's definitely sort of a inflection point that comes with that when you have enough people on it and have the critical mass. So we think that's part of it. As Adam mentioned, as prepared remarks, we are taking steps to push as hard as we can to get to that inflection point, whenever and how many patients that may be. We've expanded the size of our commercial team. We're expanding our marketing efforts coming into 2025. So yeah, I mean, is it possible? I still can't promise it. I mean, I don't think the 15 to 20% quarter over quarter steady growth that we've had thus far is problematic. I think it's pretty darn good and will continue to bring us to a blockbuster within a short amount of time. But yes, I think it is also possible that the growth rate could accelerate as we get into 2025. Adam, you want to tackle the one about the hospital setting and the percentage of patients that come from hospitals?

Yeah, yeah. So, Corinne, it's probably 60 to 65 percent of patients are being seen in the hospital setting. That's why we're We think having continued expansion into that hospital segment is encouraging, and it is now the fastest-growing segment, as I mentioned in my prepared remarks, and it is where the majority of the patients in the U.S. today are being treated.

Helpful. Thank you, guys.

Thank you.

Thank you. Next question today is coming from Prakhar Agarwal from Cancer for Children, United Airlines.

Hi, good morning, and thank you for taking my questions, and congrats on the quarter. Maybe firstly, now that Subtitle Cruise has launched, what are you seeing on the ground in terms of where it's gaining more share from, even qualitatively? And second question, you'll start generating, obviously, a lot of cash over the next few years. Maybe on the broader capital allocation priorities, is there any plans to expand the share buyback program or any any other mechanisms you can explore on the capital allocation front.

Sure. Thanks, Parker. Adam, you want to talk about what we've seen in competitive dynamics in the market recently? Sure.

Yeah, so, Prakash, thanks for the question. You know, we've seen no impact from Okavisanovo to date. You know, we had, as I mentioned in the prepared remarks, we had the best month of enrollments ever in October. So, no impact as far as we can tell right now.

And, Prakash, in terms of allocation of cash, yeah. Well, Sean did mention we started off conservatively with the share buyback program. It is something that we're committed to continuing on an ongoing basis. So, yeah, we do believe we'll be allocating over time more cash to share buybacks. But in addition, you know, as Adam, again, in his prepared remarks, as I alluded to in the prior answer, you know, we're committed to expanding the – the use of Breon V. Uh, so obviously we're going to be allocating cash toward continuing to, to build and grow our team, uh, continue to build and grow our marketing efforts, uh, which, you know, as, as everyone has followed us closely knows, we started out with a pretty modest, uh, marketing budget when we launched in 23. And I think by the time it gets to 25, we'll have a pretty healthy marketing budget. So again, I think we're, We're leaning into the opportunity we see Brionvi as a blockbuster brand, and we're going to make sure we try to get there as quickly as we can. So we will be using cash and investing in those activities. And as part of that, again, we'll be investing in these clinical programs that you heard about earlier, right? So we're going to be running, more likely than not, several randomized trials commencing in 2025. for, you know, faster infusions, skipping the doses, so stream on the front end, and, of course, sub-Q, which is obviously the highest of the priorities of that grouping. So we're going to make investments in those as well. So that's where some of the excess cash goes. Obviously, as we mentioned, Azure Cell is moving forward, and we're excited about the potential there. And then lastly, our eyes are peeled and our business development program is active. And if we see something that we think really augments and complements what we're doing, we're going to make investments there as well. So I think we've got plenty of potential uses for the excess cash, although we're not dogmatic about how it gets spent, except I'd say on the front end with the investments in making sure Brionte gets as quickly as possible to that blockbuster level.

Thank you. Next question is coming from Roger Song from Jefferies. Your line is now live.

Great. Congrats for the call, and thank you for taking my question. Most of my questions related to Breonvia have been answered, and then maybe just a follow-up on the capital allocation for those additional pipeline. So one is in terms of the Breonvia expanding to non-MS indication. when you start the trial later this year, and then would you be able to give us, provide some proof concept data to support the plan? Number one. Number two is in terms of the allogeneic cell therapy, do you expect to give us some data update next year? And then what will be the principle to share the data in terms of the number of patients and then the maturity of the data? Thank you.

Yeah, thanks, Roger. So I'll start second since it's a fresh question, and I'll work backwards. So the Azercel question. Yeah, I mean, look, we're hopeful to get that study started later this year. So we've got two months left to put our first patient in. If not, it'll be early next year. The cadence of data coming out of that trial, I think, is yet to be determined. You know, let's hopefully get some patients on as quickly as we can it's you know the logistics of these trials and the ability to put patients on rapidly is not the same as working with other biologics so but if we can get you know decent number of patients on as quickly as we can hopefully we can get some data out sometime next year but I wouldn't anticipate any available data until the second half and more likely than not second half of the year but again it's hard to really tell how fast we can enroll, although, again, historically, these studies have been enrolled slowly. So let's keep a hopeful eye on that because I do think it has a lot of promise in the areas in which we intend to study, particularly progressive MS and some other areas that we have slated to look into. So TBD on that one, Roger, will keep you posted. And in terms of the Burundi outside MS plans, again, I could say from the beginning of the year, we did note that that was probably the lowest of our near-term interests and priorities. I think we are working toward getting some patients on non-MS indications before the end of this year still, and we can report on that if and when it happens. I think part of the challenge in our plans outside of MS right now are really, you know, evaluating all the options. I mean, there's been so much new CD20 and B-cell data that's come out across multiple disease areas that we've been really taking our time, and I know we've said this before, but with new information gives us more options to look at and decide. And it's also, you know, the thought of whether it's an IV opportunity or potentially sub-Q opportunity as we move into some of these other indications. So I don't have any specifics to discuss today, but it is definitely on the radar screen. The team is working on putting non-MS patients into trials this year, and the commercial team certainly is helping us to evaluate what the next best indications are going to be. And I'm assuming 2025 we'll talk more about that and we'll get that up and running.

Thank you. We've reached the end of our question and answer session. I'd like to turn the floor back over for any further closing comments.

Great. Thank you. And thanks again, everyone, for joining us on today's call. We look forward to continuing the positive momentum into the end of the year and into next year. And as discussed today, we'll continue to be focused on several key priorities. First, expanding our BrionV launch effort, including building out our commercial footprint and increasing our spend in marketing. Next, advancing our BrionV expansion initiatives through our subcutaneous development, our enhanced switch study, and exploring new indications for BrionV. And finally, commencing our phase one AcerCell and Progressive MS, as well as looking at opportunities to expand our pipeline. With that, I'd like to close by thanking those with MS and their healthcare providers that put their trust in TG and BrionV and our loyal shareholders for their support. And once again, the whole team at TG for making it all happen. Have a great day.

Thank you. That does conclude today's teleconference webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.